Adjuvant SOX chemotherapy versus concurrent chemoradiotherapy after D2 radical resection of locally advanced esophagogastric junction (EGJ) adenocarcinoma: study protocol for a randomized phase III trial (ARTEG)

Xiangdong Cheng (chengxd@zjcc.org.cn)
Zhejiang Cancer Hospital

Jinwen Shen
Zhejiang Cancer Hospital

Xiu Zhu
Zhejiang Cancer Hospital

Yian Du
Zhejiang Cancer Hospital

Yuan Zhu
Zhejiang Cancer Hospital

Pengfei Yu
Zhejiang Cancer Hospital

Litao Yang
Zhejiang Cancer Hospital

Zhiyuan Xu
Zhejiang Cancer Hospital

Ling Hang
Zhejiang Cancer Hospital

Yunli Zhang
Zhejiang Cancer Hospital

Yanqiang Zhang
Zhejiang Cancer Hospital

Luying Liu
Zhejiang Cancer Hospital

Research Article

Keywords: Esophagogastric junction adenocarcinoma, D2 radical resection, adjuvant chemoradiotherapy
Abstract

Background

Survival benefit of adjuvant radiotherapy for locally advanced gastric cancer following gastrectomy plus D2 lymphadenectomy has always been controversial. Esophagogastric junction (EGJ) adenocarcinoma, which is usually classified as gastric cancer in East Asia, often has a higher locoregional recurrence rate after operation because of its special anatomical characteristics. The aim of this study is to determine whether adjuvant radiotherapy can improve survival of locally advanced EGJ adenocarcinoma after D2 radical resection.

Methods

In this phase III, randomized, open label, controlled trial, we plan to recruit 378 patients with Siewert type II and III adenocarcinoma of EGJ, who had undergone transabdominal radical surgery and D2 lymphadenectomy, and were divided into pathological stage IIB to IIIC. All patients will be randomized 1:1 to receive either adjuvant chemotherapy alone (control group) or adjuvant chemotherapy plus chemoradiotherapy (experimental group). Patients allocated to control group will receive eight cycles of S-1 plus oxaliplatin (SOX), while experimental group will receive two cycles of SOX followed by 45-Gy RT combined with S-1 and four additional cycles of SOX. The primary endpoint is three-year disease free survival rate (DFS). The secondary endpoints are three-year overall survival rate (OS), three-year locoregional recurrence free survival rate (LRFS), three-year distant metastasis free survival rate (DMFS), and quality of life (QoL).

Discussion

In the past, the adjuvant treatment of EGJ adenocarcinoma need to draw on the experience of esophageal adenocarcinoma or gastric adenocarcinoma. In this study, EGJ adenocarcinoma is considered as an independent disease, and the conclusion will provide evidence for optimal adjuvant therapy of locally advanced EGJ adenocarcinoma after D2 radical resection.

Trial registration: ClinicalTrials, NCT03973008. Registered 1 June, 2019. (retrospectively registered), URL: https://register.clinicaltrials.gov/prs/app/action/SelectProtocol?sid=S0008YDZ&selectaction=Edit&uid=U0000NS4&ts=2&cx=-7bsqxg

Background

Gastric cancer is one of the most threatening cancers, which ranked fifth in global cancer incidence and third in global mortality [1]. Surgical resection still remains the only radical treatment option for gastric cancer, while radical resection plus D2 lymph node dissection is currently the standard surgical procedure [2].
For locally advanced gastric cancer, the locoregional recurrence rate and distant metastasis rate are still high after D2 radical resection [3–4], leading to poor prognosis of these patients. Therefore, adjuvant chemotherapy after radical surgery is currently recommended for all locally advanced gastric cancer [5]. However, the value of adjuvant radiotherapy after radical gastrectomy for gastric cancer has always been controversial [6]. Previous clinical studies have shown that adding adjuvant radiotherapy to chemotherapy does not seem to bring additional survival benefits to gastric cancer patients undergoing D2 radical resection [7].

In the past, the treatment of esophagogastric junction (EGJ) adenocarcinoma was based on the principles of esophageal cancer or gastric cancer. But it is by now increasingly recognized that EGJ adenocarcinoma is an independent tumor entity [8]. Due to the particularity of its anatomical location, the thoroughness of surgery for EGJ adenocarcinoma, especially in the aspect of surgical margin and extent of lymph node dissection [9], is not comparable to distal gastric cancer. Logically, there is a possibility of benefit from adjuvant radiotherapy for EGJ adenocarcinoma. To evaluate the role of adjuvant radiotherapy in EGJ adenocarcinoma, we initiated this prospective, randomized controlled trial.

Rationale for this trial

EGJ adenocarcinoma is a kind of tumor with high heterogeneity [10]. At present, Siewert classification is commonly used for selecting therapeutic strategies [11]. The staging and treatment strategies of type I often refer to esophageal cancer, while type II/III tumors are treated using strategies of gastric cancer, especially in East Asia. For Siewert type II/III cancer with a length of esophageal invasion ≤3 cm, there is a general consensus in Japan that it should be treated by an abdominal, transhiatal approach [9]. Transabdominal surgery has the advantages of thoroughness of abdominal lymph node dissection and a low rate of complications, but it also has some shortcomings such as limited proximal margin, poor surgical view of lower mediastinum, and inability to perform middle or upper thoracic lymphadenectomy.

In Europe, neoadjuvant chemoradiotherapy is the standard treatment modality for esophageal and EGJ cancers [12]. The CROSS study, which compared preoperative chemoradiotherapy plus surgery with surgery alone for esophageal and EGJ cancers, showed that the R0 resection rate was significantly increased, and the overall survival rate was also improved (49.4 months vs. 24 months) in the neoadjuvant chemoradiotherapy group [13]. However, postoperative modality is advocated by clinicians in Asian. We therefore initiated a prospective, randomized controlled study to assess the hypothesized improvement of disease-free survival for locally advanced EGJ adenocarcinoma by adding radiotherapy to adjuvant chemotherapy.

Methods

SOX regimen was used for adjuvant chemotherapy:

- Oxiplatin 130 mg/m2 given intravenously on day 1
- S-1 given orally twice a day (half an hour after breakfast and dinner) for 14 consecutive days, and the dose of S-1 is shown in Table 1

- Repeated every 3 weeks

### Table 1

| Patient's body surface area (m²) | S-1 single oral dose |
|---------------------------------|----------------------|
| < 1.25                          | 40mg                 |
| ≥ 1.25 – 1.5                    | 50mg                 |
| ≥ 1.5                           | 60mg                 |

**Concurrent chemoradiotherapy regime**

- Technique of irradiation: intensity-modulated radiation therapy

- Preparation prior to CT simulation: fast 4 hours and drink 100 ml of water (including 5 ml of contrast agent) 30 minutes prior to scan; patients with remnant stomach drink additional semiliquid diet (like congee) 10 minutes before scanning

- Technique of simulation: patients in the supine position with forearm on forehead, and use custom immobilization device (e.g. thermoplastic mask) to fix body from lower thorax to lower abdomen. The scanning range is from the apex of lung to the pelvic inlet, with 5 mm slice thickness. Intravenous contrast should be used whenever available unless allergic to contrast, old age, or with serious complications.

- Irradiation field: the clinical target volume (CTV) include anastomosis with a 3-cm margin in the cranio-caudal direction, and regional lymph node drainage area [No.110 (below carina), 20, 1–3, 7–9, 11 (proximal 1/3),16a1-2]. The planning target volume (PTV) will be obtained by expanding the CTV by 5–7 mm in radial direction, and by 10 mm in cranio-caudal direction.

- Dose prescription and fractionation: a total dose of 45 Gy at 1.8 Gy per day, 5 days per week, for 5 weeks. Dose prescription and recording should comply with the recommendations of the ICRU 83.
- Organ at risk (OAR) volume definition and dose constraints: the complete volumes of the remnant stomach, the liver, the kidneys, the lungs and the heart have to be delineated. Intestine and spinal cord must be outlined the volume between above and below 2 cm range of PTV. In this study, the normal tissue dose constraints is shown in Table 2.

- Concurrent chemotherapy: S-1 given orally twice a day (half an hour after breakfast and dinner), Monday to Friday, during radiotherapy, and the dose of S-1 is shown in Table 1

| Organ             | Dose Constraints                  |
|-------------------|-----------------------------------|
| Remnant stomach   | $V_{40} < 50\%$ (no hot spot)     |
| Liver             | $V_{30} < 40\%$                   |
|                   | $D_{mean} < 18\text{ Gy}$         |
| Kidney            | $V_{20} < 30\%$                   |
| Lung              | $V_{20} < 20\%$                   |
| Heart             | $V_{30} < 30\%$                   |
| Intestine         | $D_{\text{max}} \leq 50\text{ Gy}$|
| Spinal cord       | $D_{\text{max}} < 40\text{ Gy}$  |

**Outcome measures**

**Primary endpoint**

The three-year DFS is the primary endpoint of this study. It is defined as the percentage of patients without locoregional recurrence, distant metastasis, or tumor-related death at 3 years measured from the date of randomization. Once a patient is lost after the last follow-up, his/her survival time will be censored at the last date the patient is known to be alive.

**Secondary endpoints**

The secondary endpoints of this study included three-year OS, three-year LRFS, three-year DMFS, and QoL.
Three-year OS is defined as the percentage of patients in this study who are still alive at 3 years measured from the date of randomization. In this study, locoregional recurrence was defined as recurrence at the anastomotic site, tumor bed, remnant stomach or regional lymph nodes site, and distant metastasis is defined as non-regional lymph node recurrence, peritoneal seeding, metastasis to other organs. Three-year LRFS and DMFS are defined as the percentage of patients who are without locoregional recurrence or distant metastasis at 3 years measured from the date of randomization respectively. EORTC QLQ-C30 and QLQ-STO22 questionnaires will be used to evaluate QoL of patients at baseline, every 4-week during treatment and every visit after treatment.

Safety reporting

Adverse events

Adverse events are defined as any adverse medical event that occurs between the inclusion in the study with the signing of the informed consent and the last visit, regardless of whether there is a causal relationship with the drugs or treatments being studied.

Adverse events include the following:

- All suspected adverse drug reactions (ADR)
- All reactions due to drug overdose, abuse, withdrawal, allergy or toxicity
- Obviously unrelated diseases, including the aggravation of pre-existing diseases
- Injury or accident
- Abnormalities found by physiological or physical examinations and requiring clinical treatment or further examination (unlike repeated validation examinations); abnormalities found in laboratory tests require clinical treatment or further investigation (unlike repeated validation tests); if these abnormalities are related to another reported event (e.g. elevated liver enzymes in jaundice patients), they should be described in the notes to the clinical event report and not listed as a separate adverse event.

Adverse Event Record

Research physicians should use concise medical terminology to report all adverse events directly observed by physicians or spontaneously reported by subjects. In addition, patients should be asked about adverse events every time they visit a doctor at the beginning of treatment, fill in the adverse event record table truthfully, record the occurrence time, severity, duration, measures taken and outcome of adverse events. Adverse events should be recorded in the Adverse Events Table of Case Report Form (CRF).
Grading of adverse events

Adverse events were classified into grades 1–4 according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (NCI-CTCAE v4.0) and the European Organization for Research and Treatment of Cancer (EORTC)/Radiation Therapy Oncology Group (RTOG) score:

- Grade 1: Mild, asymptomatic or mild symptoms, only clinical diagnosis or symptoms, can be tolerated
- Grade 2: Medium, has a certain impact on normal life
- Grade 3: Severe, unable to carry out normal daily activities; leading to hospitalization or prolonged hospitalization
- Grade 4: Life threatening, if emergency intervention is needed, otherwise there is a direct risk of death
- Grade 5: Death

Serious adverse events

When an adverse event meets one or more of the following criteria, it is classified as a serious adverse event (SAE):

- Causing death
- Life-threatening
- Need for hospitalization or extended hospitalization
- Causing persistent or severe disability or dysfunction
- Congenital deformity or birth defect
- Major medical events

Any serious adverse events in the course of clinical research must be reported by fax or telephone to the ethics committee and the principal investigator within 24 hours. The principal investigator will collect data and reports according to SFDA and Ministry of Health’s reporting requirements on adverse reactions.
Researchers must fill in a serious adverse event form to record the occurrence time, severity, duration, measures taken and outcome of serious adverse events.

Once SAE occurs, all antineoplastic therapy should be discontinued immediately, and the relationship between adverse events and research drugs or radiotherapy should be assessed, and appropriate symptomatic and supportive treatment should be given until the patient recovers or remains stable.

**Dose Modification**

According to CTCAE v4.0, the toxicities during the study should be graded. When adverse drug reactions occur, the dose of drugs should be reduced according to the following principles, or even discontinue treatment. Details of each patient's dose reduction and withdrawal should be recorded in the CRF table.

**Dose reduction/withdrawal principle for adverse drug reactions of concurrent chemotherapy and adjuvant chemotherapy**

- No special treatment should be given when grade 1 adverse reactions occur

- S-1/oxaliplatin should be discontinued and given symptomatic treatment when grade 4 leucopenia, grade 3 gastrointestinal adverse reactions, grade 2 anemia and thrombocytopenia, and grade 2 liver and kidney dysfunction occur. If the grade of adverse reactions dropped to 0–1 within 5 days after treatment, the initial dose of S-1/oxaliplatin was restored; if not, consideration should be given to reducing dose of S-1/oxaliplatin to 80% of the initial dose. If the above adverse reactions persist for more than 3 days after symptomatic treatment and dose reduction, or other adverse reactions with new grade 2 or higher occur again, S-1/oxaliplatin should be terminated.

- When other grade 3 adverse reactions occur, the treatment principle is the same as that of corresponding grade 2 adverse reactions

- If any grade 4 adverse reactions occur, the concurrent chemotherapy or adjuvant chemotherapy should be stopped and not continued.

**Principles of interruption or discontinuation of radiotherapy**

- When the acute grade 3 radiation toxicities occurs, radiotherapy should not be interrupted and symptomatic treatment should be given. If it does not recover to grade 0–1 within 7 days, radiotherapy should be interrupted, and restarted after the grade of toxicity return to 0–1. If the same toxicities of above grade 2 reoccur, radiotherapy should be terminated. When radiotherapy is terminated, S-1 should be terminated at the same time.
- Any grade 4 adverse reactions except leukopenia occurred, radiotherapy should be discontinued. When the adverse reactions recover to grade 0–1, restart radiotherapy, but not chemotherapy.

- Dose of radiation should not be adjusted unless new adverse reactions occur or the original adverse reactions are aggravated.

**Follow-up**

Patients should be followed up once every 3 months within 2 years after operation and once every 6 months 2 years after operation until 5 years. Follow-up contents include physical examination, performance status monitoring, weight monitoring, routine blood test, blood chemistry, tumor markers (including CEA and CA19-9), adverse events and QoL assessment. Chest, abdominal, and pelvic CT should be performed every 6 months, and gastroscopy is recommended once a year. If new symptoms or symptoms worsen, patients should receive follow-up visit at any time. The recurrence and/or metastasis must have biopsy or clinical imaging evidence, and the time and location of recurrence and/or metastasis should be recorded in detail.

**Statistical analysis**

In this study, the sample size was estimated by statisticians. The 3-year DFS of the experimental group is expected to be increased from 47–60% (δ = 0.13), which provides strong evidence for adjuvant treatment of locally advanced EGJ adenocarcinoma. With a one-sided alpha = 0.05 and 1-β = 0.8, 172 per group would be necessary, and 206 endpoint events need to be observed. Given an estimated dropout rate of 10%, the required total sample size would be 378. Patients enrolled in this study would be randomly divided into experimental group and control group, stratified by whether the EGJ is invaded or not and by postoperative stage. The ratio of the two groups was 1:1.

The analysis was based on the intention-to-treat (ITT) population. The ITT population should include all patients receiving randomization. Per-protocol (PP) population should include all patients who received at least two cycles of chemotherapy and completed radiotherapy for experimental group and received at least four cycles of chemotherapy for control group.

Comparison of baseline data between the two groups: if the quantitative data is normal distribution, t test is used; if it is not, rank sum test is used; χ² test is used for qualitative data. Survival analysis is carried out by SPSS software package. Log rank χ² analysis is used for comparison between the two groups, and Cox regression model is used in multivariate analysis. χ² test is used to compare the recurrence rate, metastasis rate and the incidence of side effects between the two groups. Two-tailed test is used, and p < 0.05 is considered statistically significant.

**Randomization, data collection and monitoring**
All potential participants will be initially screened by the designated pathologists, and then further screened according to the inclusion criteria and exclusion criteria by the designated clinicians. Those eligible subjects who signed the consent will be randomized to either experimental group (adjuvant chemotherapy plus chemoradiotherapy) or control group (adjuvant chemotherapy alone) in a ratio of 1:1. Randomization will be stratified by whether the EGJ is invaded or not and by postoperative stage. We use a mobile application software, developed by Fudan University Biostatistics Central Office (Shanghai, China), to perform randomization. Data management and storage will be carried out by an independent data collection group (yitu-med, https://edcs.yitu-med.com), and personal information will be encoded. The principal investigator and core investigators will review the enrollment progress and data entry.

**Ethics**

This study was carried out according to the Declaration of Helsinki. The protocol, the informed consent form and the case report form have been reviewed and approved by the medical ethics committee of our hospital (IRB-2019-196), and the main members who participated in the study have obtained the certificate of the Good Clinical Practice (GCP) course.

Participation in this study is completely voluntary. All patients will be informed of the study process, benefits, costs, potential adverse reactions and other alternative treatment options in detail before entering this study, and then sign the informed consent. All the signed informed consent will be kept by the principal investigator. After entering this study, patients could withdraw from the study at any time for any reason and receive other alternative treatment.

**Discussion**

The role of adjuvant radiotherapy after radical resection for gastric cancer has always been controversial. The classic INT-0116 study [14], which showed that radiation therapy for postoperative gastric cancer patients improved three-year DFS and OS compared with surgery alone, could not prove the benefit of adjuvant radiotherapy after radical D2-resection due to limited lymph node dissection in that study (D2 dissection accounted for only 10% ). The Korean ARTIST 1 study [7], which included patients underwent D2 lymphadenectomy, indicated that the addition of radiotherapy to adjuvant chemotherapy did not significantly reduce the recurrent rate after surgery. Subgroup analysis suggested that pathologic node-positive patients might benefit from postoperative irradiation. However, according to the interim results of ARTIST 2 study[15], no difference in three-year DFS were found for patients with lymph node metastasis after D2-resection when adding irradiation to SOX chemotherapy. Although the final results of ARTIST 2 study have not yet been published, it is widely acknowledged that the benefit of adjuvant radiotherapy is quite limited for gastric cancer after radical D2-resection.

However, it is worth noting that, the majority of patients enrolled in trials on gastric cancer in Asia were distal gastric cancer, while the proximal gastric cancer were fewer. For example, cancer of the gastric antrum and gastric body accounted for 60% of the patients in ARTIST 1 study [7], while proximal gastric cancer accounted for only 20%. Due to the particularity of anatomical location, the benefit of
postoperative radiotherapy for EGJ cancer cannot be directly analogized by the conclusions of studies on gastric cancer.

Adenocarcinoma of the esophagogastric junction have the characteristic of high heterogeneity. Siewert classification, which is a classification method based on the location of tumors, is being widely used in guiding the clinical treatment of EGJ adenocarcinoma. On the view of surgical approach, Siewert type I tumor is usually treated by transthoracic approach, while type II/III tumors have two ways of surgery: transthoracic approach and transabdominal approach. A phase III trial in Japan recruited patients with Siewert type II/III EGJ adenocarcinoma, whom were randomly divided into the left thoracoabdominal approach group (LTA) and the transhiatal approach group (TH). The interim analysis showed that the risk of death in LTA group was 36% higher than that in TH group [16], so the trial was closed ahead of schedule and concluded that for type II/III tumors, the left thoracoabdominal surgery was inferior to the transhiatal surgery. Recently, a meta-analysis of 8 studies, involving 1155 patients with EGJ cancer underwent transthoracic surgery or transhiatal surgery, found a shorter hospital stay, lower 30-d hospital mortality, and decreased pulmonary complications in the transhiatal group. Because of a potential survival advantage for type III tumors in the transhiatal group, the authors recommended the transhiatal approach as the optimal choice, especially for Siewert type III tumors [17].

However, both transabdominal and transthoracic operations often have the shortcomings of limited proximal or distal margin, incomplete dissection of mediastinal or abdominal lymph nodes, which make the local recurrence rate of EGJ cancer unsatisfactory. So, multimodal therapy has become the standard treatment strategy for locally advanced EGJ tumors. The MAGIC study in the UK, which compared the efficacy of perioperative chemotherapy with surgery alone for resectable gastroesophageal cancer, showed that the 5-year survival rate of the perioperative chemotherapy group increased by 13% compared to that of surgery alone group (5-year OS rate, 36% vs. 23%) [18]. The France FNCLCC/FFCD study is similar to the MAGIC study, but included more EGJ cancer (account for 60%), and the survival rate of the chemotherapy-treated patients increased by 14% (5-year OS rate, 38% vs. 24%) [19]. In Asia, however, clinicians and patients prefer postoperative therapeutic modality for three reasons: first, the preoperative clinical stage is not as accurate as the postoperative pathological stage, which leads to over treatment of some early patients; second, the toxicity caused by neoadjuvant radiotherapy may preclude surgery or increase post-operation complication [20]; third, the frequency of distal intramural spread in irradiated tumor is increased, which results in the difficulty of safety margin determination [21]. Therefore, we designed this phase 3, randomized controlled study to provide an optimal adjuvant treatment strategy for locally advanced EGJ cancer.

**Trial Status**

The protocol version number and date: Version 2.1, 29 November, 2019

The date of recruitment start: 1 July, 2019
The expected date of recruitment complete: 30 June, 2022

**Abbreviations**

ADR: Adverse drug reactions; ALT: Alanine-glutamic transaminase; ANC: Absolute neutrophil count; AST: Alanine transaminase; CRF: Case report form; CTV: Clinical target volume; DFS: Disease free survival rate; DMFS: Distant metastasis free survival rate; ECOG: Eastern Cooperative Oncology Group; EORTC: European Organization for Research and Treatment of Cancer; GCP: Good clinical practice; Hb: Hemoglobin; ITT: Intention-to-treat; LRFS: Locoregional recurrence free survival rate; OAR: Organ at risk; OS: Overall survival rate; Pt: Platelet; PTV: Planning target volume; QoL: Quality of life; RTOG: Radiation Therapy Oncology Group; SAE: Serious adverse event; SOX: S-1 plus oxaliplatin; WBC: White blood cell

**Declarations**

**Ethics approval and consent to participate**

The protocol has been reviewed and approved by the medical ethics committee of Cancer Hospital of the University of Chinese Academy of Sciences (IRB-2019-196), and the study has also been registered in ClinicalTrial.gov (NCT03973008, registered on June 1, 2019).

**Consent for publication**

Not applicable

**Availability of data and materials**

Not applicable

**Competing interests**

The authors declare that they have no competing interests

**Funding**

None

**Authors' contributions**

LYL and XDC made major contributions to design the study and revise the manuscript. JWS wrote the protocol and the manuscript. XZ was responsible for pathological examination. YZ was involved in
radiotherapy plan reviewing. YAD, PFY, LTY, ZYX and YLZ carried out surgery. LH and YQZ performed the follow-up and data analysis. All authors read and approved the final manuscript.

Acknowledgements

Not applicable

References

1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018, 68(6):394–424.
2. Songun I, Putter H, Kranenbarg MK, et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. The Lancet Oncology, 2010, 11(5):439–49.
3. Chang JS, Kim KH, Keum KC, et al. Recursive partition analysis of peritoneal and systemic recurrence in patients with gastric cancer who underwent D2 gastrectomy: Implications for neoadjuvant therapy consideration. J Surg Oncol, 2016, 114(7):859–64.
4. Wang SB, Qi WX, Chen JY, et al. Competing risk nomogram predicting initial loco-regional recurrence in gastric cancer patients after D2 gastrectomy. Radiat Oncol, 2019, 14(1):128.
5. Noh SH, Park SR, Yang HK, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. The Lancet Oncology, 2014, 15(12):1389–96.
6. Xu J, Zhu J, Wei Q. Adjuvant Radiochemotherapy versus Chemotherapy Alone for Gastric Cancer: Implications for Target Definition. J Cancer, 2019, 10(2):458–66.
7. Lee J, Lim DH, Kim S, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol, 2012, 30(3):268 – 73.
8. Goetze TO, Al-Batran SE, Berlth F, Hoelscher AH. Multimodal Treatment Strategies in Esophagogastric Junction Cancer: a Western Perspective. J Gastric Cancer, 2019, 19(2):148–56.
9. Zhang S, Orita H, Fukunaga T. Current surgical treatment of esophagogastric junction adenocarcinoma. World J Gastrointest Oncol, 2019, 11(8):567–78.
10. Mönig SP, W Schröder, Beckurts KT, et al. Classification, diagnosis and surgical treatment of carcinomas of the gastroesophageal junction. Hepato-gastroenterology, 2001, 48(41):1231.
11. Siewert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg, 1998, 85(11):1457–9.
12. Ikebe M, Morita M, Yamamoto M, et al. Neoadjuvant therapy for advanced esophageal cancer: the impact on surgical management. General Thoracic Cardiovascular Surgery, 2016, 64(7):386–94.
13. Hagen P. Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med, 2012;366(22):2074–84.

14. Macdonald JS. Smalley SR, Benedetti J, et al Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med, 2001;345:725–30.

15. Park SH. Zang DY, Han B, et al. ARTIST 2: Interim results of a phase III trial involving adjuvant chemotherapy and/or chemoradiotherapy after D2-gastrectomy in stage II/III gastric cancer (GC). J Clin Oncol, 2019, 37(15_suppl):4001–1.

16. Mitsuru Sasako Takeshi, Sano Seiichiro, Yamamoto, et al. Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial. Lancet Oncol, 2006;7(8):644 – 51.

17. Wei MT. Zhang YC, Deng XB, et al. Transthoracic vs transhiatal surgery for cancer of the esophagogastric junction: A meta-analysis. World J Gastroenterol, 2014;20(29):10183-92.

18. Cunningham D. Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med, 2006,355(1):11–20.

19. Ychou M. Boige V, Pignon J P, et al. Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial. J Clin Oncol, 2011, 29(13):1715–21.

20. Wong RK. Jang R, Darling G. Postoperative chemoradiotherapy vs. preoperative chemoradiotherapy for locally advanced (operable) gastric cancer: clarifying the role and technique of radiotherapy. J Gastrointest Oncol, 2015, 6(1):89–107.

21. Mezrh JJ. Smith KD, Fichera A, et al. Presence of distal intramural spread after preoperative combined-modality therapy for adenocarcinoma of the rectum: What is now the appropriate distal resection margin? Surgery, 2005, 138(4):658–64.

Figures
Figure 1

Flow chart of the study

Siewert II/III AC of EGJ after D2 resection pathological stage IIB to IIIC

Eligible and sign the informed consent

Randomization stratified by EGJ invaded or not & postoperative stage

Experimental group

SOX × 2 cycles

45Gy RT + S-1

SOX × 4 cycles

Control group

SOX × 8 cycles
Figure 2

Schedule of enrollment, interventions, and assessments

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- Additionalfile1.doc